Effective treatment of coprophagia in a patient with schizophrenia with the novel atypical antipsychotic drug perospirone.
Here we report on a patient with schizophrenia who suffered from medication-refractory coprophagia. Although there were few cases in which psychotropic medication was effective against coprophagia, we encountered a patient with schizophrenia in whom coprophagia rapidly disappeared after treatment with perospirone, a novel atypical antipsychotic drug of the serotonin-dopamine antagonist (SDA) type. Perospirone has a uniquely high affinity for serotonin-1A receptors, and it could be speculated that perospirone, as a serotonin-1A receptor agonist combined with SDA, may have greater efficacy for treatment-refractory symptoms of schizophrenia. Thus, perospirone is an agent with possible efficacy for medication-refractory schizophrenia.
Harada
K I
KI
Yamamoto
K
K
Saito
T
T
D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001921:Brain / Q000187:drug effects; D005500:Follow-Up Studies; D064106:Human Coprophagia / Q000188:drug therapy* / Q000523:psychology; D006801:Humans; D007211:Indoles / Q000009:adverse effects / Q000627:therapeutic use*; D054833:Isoindoles; D008297:Male; D008875:Middle Aged; D044282:Receptor, Serotonin, 5-HT1A / Q000187:drug effects; D012565:Schizophrenic Psychology; D013844:Thiazoles / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D007211:Indoles; D054833:Isoindoles; D013844:Thiazoles; D044282:Receptor, Serotonin, 5-HT1A; C065533:perospirone